This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms Investigator's sites: 80-90 sites in Germany and Austria Estimated duration of observation of an individual patient: 10 years maximum Objectives * To register all patients with AML and related neoplasms, newly diagnosed or relapsed/refractory in all AMLSG participating centers (completeness) * To perform rapid analyses of disease-related genetic markers (incidences, treatment recommendations) * To assess patient and family history, as well as patient characteristics * To evaluate treatment response (CR, CRh, CRi) and outcome data (event-free survival \[EFS\], relapse-free survival \[RFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\]) * To evaluate the impact of measurable residual disease (MRD) by different methods * To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) * To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue; e.g., skin biopsy, finger nails, hairs, sputum, or urine)
Study Type
OBSERVATIONAL
Enrollment
50,000
Medizinische Universität Graz
Graz, Austria
RECRUITINGMedizinische Universität Innsbruck
Innsbruck, Austria
RECRUITINGKrankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.
Linz, Austria
SUSPENDEDKrankenhaus der Elisabethinen Linz GmbH
Linz, Austria
incidence of disease-related genetic markers
To perform rapid analyses of disease-related genetic markers (according to International Consensus Classification 2022) (incidences, treatment recommendations)
Time frame: 4 weeks
Event-free survival
To assess patient and family history, patient characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])
Time frame: 10 years
Cumulative incidence of relapse
To assess patient and family history, patient characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])
Time frame: 10 years
Cumulative incidence of death
To assess patient and family history, patient characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])
Time frame: 10 years
Overall survival
To assess patient and family history, patient characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])
Time frame: 10 years
Treatment decision (intensive, non-intensive, investigational)
To perform rapid analyses of disease-related genetic markers (according to ICC 2022) (incidences, treatment recommendations)
Time frame: 1 year
quality of life
Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, socioeconomics, and demographics according to Messerer D et al (2008), 6, 12 and 24 months after registration.
Time frame: 2 years
Geographical representation
Geographical representation of patients through collection of patients zip codes
Time frame: 1 day
Response to therapy
Rate of response: complete remission (CR), CR with partial hematologic recovery (CRh); CR with incomplete hematologic recovery (CRi)
Time frame: 1 year
Relapse-free survival
Time frame: 10 years
Measurable residual disease (MRD)
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Kepler Universitätsklinikum GmbH
Linz, Austria
RECRUITINGLandeskrankenhaus Feldkirch
Rankweil, Austria
RECRUITINGUniversitätsklinikum der PMU Landeskrankenhaus Salzburg
Salzburg, Austria
RECRUITINGHanuschkrankenhaus Wien
Vienna, Austria
RECRUITINGKlinikum Aschaffenburg
Aschaffenburg, Germany
RECRUITINGKlinikum Augsburg
Augsburg, Germany
SUSPENDED...and 84 more locations